Entero Healthcare Solutions approved the Unaudited Financial Results for the quarter and nine months ended December 31, 2025, along with Limited Review Reports. The Board also approved the grant of 5,000 fresh Employee Stock Options under the 2023 Plan. Furthermore, the company officially cancelled the previously announced acquisition of Khera Medisolutions Private Limited and AV Medisolutions Private Limited due to commercial reasons. The meeting took place on February 12, 2026.
Outcome of Board Meeting Held on February 12, 2026
The Board of Directors of Entero Healthcare Solutions Limited convened on February 12, 2026, commencing at 03:00 P.M. IST and concluding at 05:30 P.M. IST, to consider and approve several key items.
Unaudited Financial Results (Standalone)
The Board approved the Unaudited Financial Results (Standalone and Consolidated) for the quarter and nine months ended December 31, 2025. These results were accompanied by unmodified Limited Review Reports issued by the Statutory Auditors. Key figures from the Standalone results indicate a strong performance trend:
- For the quarter ended December 31, 2025 (Unaudited), Revenue from operations stood at Rs. 1,067.36 Million, resulting in a Profit After Tax of Rs. 8.05 Million.
- For the nine months ended December 31, 2025 (Unaudited), Total Income reached Rs. 3,430.76 Million, with Profit After Tax totaling Rs. 134.59 Million.
Employee Stock Option Grant
Pursuant to the recommendation of the Nomination & Remuneration Committee, the Board noted the approval for the grant of fresh 5,000 (Five Thousand only) Employee Stock Options. These options are issued under the existing “Entero Employee Stock Option Plan 2023”. The options were granted at an exercise price of INR 804 per option.
Cancellation of Proposed Acquisitions
The Board formally approved the cancellation of the proposed acquisition of Khera Medisolutions Private Limited and AV Medisolutions Private Limited. These proposed acquisitions had previously been intimated on May 27, 2025, and August 08, 2025, respectively. The decision to cancel was driven by commercial reasons.
ESOP Details (Annexure 2 Summary)
The details regarding the ESOP grant confirm compliance with SEBI (SBEB) Regulations, 2021. The total number of shares covered is 5,000 Equity Shares. Options granted under the plan will vest no earlier than 1 (One) Year and no later than 4 (four) years from the grant date. The exercise period is set at 8 (Eight) years from the vesting date.
Unaudited Financial Results (Consolidated Highlights)
The consolidated financial statements also showed growth, with Total Income for the nine months ended December 31, 2025 reaching Rs. 46,965.14 Million, resulting in a Profit After Tax of Rs. 1,007.12 Million for the same period.
Source: BSE
